Bayer Kogenate FS

Attention: Your browser does not support Javascript, or Javascript support has been disabled. This web site utilizes the latest Internet technology, and in order to experience the full functionality of this web site you will need to ensure that Javascript is enabled.




































	General Conditions of Use Privacy Statement Imprint

	This website is intended for U.S. Audiences Only.

	© 2008 Bayer HealthCare LLC BAYER, the Bayer Cross, and Kogenate are registered trademarks of Bayer BIO-SET is a trademark of Biodome SAS

Living with Hemophilia

In this section you'll find a variety of information explaining hemophilia, its symptoms (including details on the mechanism of blood coagulation and a molecular-eye-view of what happens at the site of a bleed), and its treatment with Kogenate^® FS.

Other hemophilia resources such as a glossary, frequently asked questions (FAQ's), a list of National Hemophilia Foundation Chapters, and links to hemophilia-related web pages are also provided.

We've also included a Kids' Corner, especially for children with hemophilia.

Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor if you have any questions about your health, your symptoms, or your therapy.

Kogenate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness, and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate® FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate® FS. For important safety and use information, please see the full prescribing information.

Please consult your health care provider prior to making any lifestyle changes. The images used on this site do not necessarily represent actual Hemophilia patients.